Retrieve available abstracts of 7 articles: HTML format
Single Articles
October 2024
CARTELLA I, Palazzini M, Sirico D, Buono A, et al Hypertrophic cardiomyopathy secondary to hydroxychloroquine toxicity in a patient
with rheumatoid arthritis.
Lancet. 2024;404:1560. PubMed
August 2024
FISHER BA, Mariette X, Papas A, Grader-Beck T, et al Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct
populations of patients with Sjogren's disease (TWINSS): week 24 results of a
randomised, double-blind, placebo-controlled, phase 2b dose-ranging study.
Lancet. 2024;404:540-553. PubMedAbstract available
COLAFRANCESCO S, Priori R Sjogren's disease: a new era for clinical trials?
Lancet. 2024;404:498-499. PubMed
February 2024
VAN DER HELM-VAN MIL AHM Abatacept in individuals with autoantibody-positive arthralgia at risk for
rheumatoid arthritis.
Lancet. 2024 Feb 14:S0140-6736(24)00055-2. doi: 10.1016/S0140-6736(24)00055. PubMed
RECH J, Tascilar K, Hagen M, Kleyer A, et al Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals
at high risk (ARIAA): a randomised, international, multicentre, double-blind,
placebo-controlled trial.
Lancet. 2024 Feb 13:S0140-6736(23)02650-8. doi: 10.1016/S0140-6736(23)02650. PubMedAbstract available
COPE AP, Jasenecova M, Vasconcelos JC, Filer A, et al Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a
randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b
clinical trial.
Lancet. 2024 Feb 13:S0140-6736(23)02649-1. doi: 10.1016/S0140-6736(23)02649. PubMedAbstract available
November 2023
DI MATTEO A, Bathon JM, Emery P Rheumatoid arthritis.
Lancet. 2023;402:2019-2033. PubMedAbstract available